MTOR and hepatocellular carcinoma: In a cancer-specific manner, EEF1A2 has been reported to promote specific pathways, for example, TGF-β/SMAD signaling in lung adenocarcinoma [37], the PI3K/AKT/mTOR pathway in hepatocellular carcinoma [12], the ERK pathway in breast cancer [56], and PI3K signaling in brain cancer [57].